ERBB2 and non-small cell lung carcinoma: Compared to HER2-mutant NSCLC, patients with NSCLC whose tumors have HER2 amplification or protein overexpression are not associated with any specific clinicopathological features, such as age, sex, smoking status, or stage at diagnosis [66,72].